<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640443</url>
  </required_header>
  <id_info>
    <org_study_id>2015/059</org_study_id>
    <nct_id>NCT02640443</nct_id>
  </id_info>
  <brief_title>Sulfamethoxazole for the Treatment of Primary PREPL Deficiency</brief_title>
  <acronym>SPPD</acronym>
  <official_title>Sulfamethoxazole for the Treatment of Primary PREPL Deficiency (In Dutch: Sulfamethoxazole Ter Behandeling Van Primaire PREPL deficiëntie)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate whether sulfamethoxazole, a sulfamide antibiotic, improves
      the symptoms of primary PREPL deficiency (hypotonia-cystinuria syndrome and isolated PREPL
      deficiency).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ptosis on myasthenia gravis composite scale</measure>
    <time_frame>Change in score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>ptosis item on the myasthenia gravis composite scale: single blinded scoring on video-images</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ptosis index</measure>
    <time_frame>Change in index between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>ptosis index, single blinded measurement on photograph</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lip length index</measure>
    <time_frame>Change in index between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>lip length index, single blinded measurement on photographs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lip purse index</measure>
    <time_frame>Change in index between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>Lip purse index, single blinded measurement on photographs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in satiety</measure>
    <time_frame>Change in Composite score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>satiety scale (visual analog); 4 questions are asked, a compositie score is made, by adding the different scores (the answers on questions 2 and 3 are counted as negative values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in myasthenia gravis composite score</measure>
    <time_frame>Change in score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>Sum of all the subscores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myasthenia gravis composite dysarthria and eye closure subscores</measure>
    <time_frame>Change in score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>scored on video</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle strength</measure>
    <time_frame>Change in strength between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>scored with hand-held manometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in complete blood count</measure>
    <time_frame>Change between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>complete blood count (development of cytopenia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycemia</measure>
    <time_frame>Change between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>Glycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal ultrasound</measure>
    <time_frame>development of kidney stones after the third week of treatment versus baseline</time_frame>
    <description>renal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in myasthenia gravis-activities of daily life</measure>
    <time_frame>Change in score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>Scale with rating of activities of daily life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neuropsychology Child Behaviour checklist</measure>
    <time_frame>Change in score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>composite score of Child Behaviour checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neuropsychology Brief</measure>
    <time_frame>Change in score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>composite score of Brief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neuropsychology Amsterdamse neuropsychologische test</measure>
    <time_frame>Change in score between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>composite score of Amsterdamse Neuropsychologische test (ANT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin</measure>
    <time_frame>Change between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF1</measure>
    <time_frame>Change between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>IGF-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGFPB3</measure>
    <time_frame>Change between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>IGFBP3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pupillometry</measure>
    <time_frame>Change between baseline/1 week after treatment stop versus third week of treatment</time_frame>
    <description>dynamic pupillometry with infrared camera</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hypotonia Cystinuria Syndrome</condition>
  <condition>Isolated PREPL Deficiency</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with sulfamethoxazole. Subjects will serve as their own control, by using the data from baseline and after treatment stop.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole</intervention_name>
    <description>60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with molecular confirmation of primary PREPL deficiency

          -  who are able to follow the study protocol (for the primary endpoint)

          -  who have given written informed consent

        Exclusion Criteria:

          -  age&lt;2m

          -  women of child-bearing age unless using a reliable method for contraception and not
             pregnant at study entrance

          -  additional diagnosis with influence on muscle force

          -  not able to follow the study protocol (for the primary endpoint)

          -  history of sulfonamide hypersensitivity

          -  diminished renal function based on serum creatinine

          -  transaminases higher than 3 times the upper limit of normal

          -  for the pupillometry: eye pathology with the exception of refractive errors, drugs
             with influence on the pupillary light reflex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Régal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <reference>
    <citation>Régal L, Shen XM, Selcen D, Verhille C, Meulemans S, Creemers JW, Engel AG. PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome. Neurology. 2014 Apr 8;82(14):1254-60. doi: 10.1212/WNL.0000000000000295. Epub 2014 Mar 7.</citation>
    <PMID>24610330</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystinuria</mesh_term>
    <mesh_term>Chromosome Deletion</mesh_term>
    <mesh_term>Intellectual Disability</mesh_term>
    <mesh_term>Muscle Hypotonia</mesh_term>
    <mesh_term>Craniofacial Abnormalities</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

